TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00903851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidoderm
Description: Patients participated in an 8-week treatment period; patients at one site were to continue treatment for the entire 8 weeks while patients at two sites were to terminate treatment after 3 weeks. Commercially available Lidoderm® (lidocaine patch 5%) was provided to each patient with up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain.
Study: NCT02284412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: At a train-of-four (TOF) ratio of 0.5: administration of neostigmine 0.06 mg/kg for reversal of neuromuscular blockade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: At a train-of-four (TOF) ratio of 0.5: administration of sugammadex 15 mg/kg for reversal of neuromuscular blockade.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water for injection
Description: At a train-of-four (TOF) ratio of 0.5: administration of placebo for spontaneous recovery of neuromuscular blockade.
Study: NCT03689413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 200 MG in 2 ML Injection
Description: 1 mg/kg or 2 mg/kg intravenous injection for each group (1 mg/kg group, 2 mg/kg group) after tracheal intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex 200 MG in 2 ML Injection
Description: 1 mg/kg or 2 mg/kg intravenous injection for each group (1 mg/kg group, 2 mg/kg group) after tracheal intubation
Study: NCT01312480

Intervention type: OTHER
Group type: OTHER
Intervention: Media Use Assessment
Description: The media use assessment (control condition) is based in part on the American Academy of Pediatrics policy statement on children and media, published in the November 2010 issue of Pediatrics. This assessment includes suggested questions on how much media per day is used and whether or not the adolescent has a television or Internet access in his/her bedroom. The adolescent will complete a one-page Media Use assessment form for this purpose, which will set the stage for relevant anticipatory guidance.
Study: NCT04494048

Intervention type: OTHER
Intervention: Endoscopic Bariatric Therapies
Description: Participation in this study will allow for data collection through medical chart review for at least 6 standard of care visits up to 1 year after consenting to participate in this registry study. The exposure of interest is total body weight loss, safety and efficacy
Study: NCT00297869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Decision Support
Description: Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
Study: NCT00556023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206 and gemcitabine
Description: Escalating doses of CP-675,206 will be administered by IV infusion on day 1 of each 84-day treatment cycles (doses of 6, 10 and 15 mg/kg are planned). Gemcitabine will be administered by IV infusion, at a fixed dose of 1000 mg/m2 on days 1 (prior to CP-675,206) and again on days 8, 15, 29, 36, 43, 57, 64, and 71. Repeated cycles of gemcitabine and CP-675,206 will be administered until patients develop progressive disease or unacceptable toxicity, or for a maximum of 4 cycles, whichever occurs first.
Study: NCT03148626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MINDI mindfulness curriculum
Description: A seven-session mindfulness curriculum implemented over six-months during pediatric internship.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Usual Education
Study: NCT03916809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMST
Description: Expiratory muscle strength training (EMST) is an exercise program designed to strengthen the muscles of expiration by increasing expiratory load during breathing exercises using either resistive or pressure threshold devices. The EMST150 is a commercially-available device considered non-significant risk (NSR). The EMST150 device will be used for this study.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: EMST
Description: Expiratory muscle strength training (EMST) is an exercise program designed to strengthen the muscles of expiration by increasing expiratory load during breathing exercises using either resistive or pressure threshold devices. The EMST150 is a commercially-available device considered non-significant risk (NSR). The EMST150 device will be used for this study.
Study: NCT04504955

Intervention type: OTHER
Intervention: Observational Non-Interventional Registry
Description: Observational Non-Interventional Registry
Study: NCT06094452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training
Description: Participants in intervention group will receive a multidomain, adaptive computerized cognitive training program (www.66nao.com) and will be required to complete at least 30 minutes of training per day (3 cycle of 5 2-min tasks), 5 days a week for 24 weeks. Multidomain coverage paradigms include working memory, calculation, processing speed, attention, executive function, and short-term and long-term memory.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Patients in control group will receive TAU for 24 weeks, which includes (1) regular medication management from the Memory Clinic, if applicable; (2) basic health education at each follow-up (face to face) and twice per month on the internet .
Study: NCT03660241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: PF 04965842 is a janus kinase (JAK) 1 inhibitor that is currently being developed for the treatment of atopic dermatitis (AD).
Study: NCT04438343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Impairment-specific and augmented intervention
Description: Balance and lower extremities strength training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Trunk and upper extremity training
Study: NCT03722355

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional RT
Description: Radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperfractionated RT
Description: Radiation therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carmustine
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Chemotherapy
Study: NCT02132754

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166
Study: NCT03703336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ROTAVIN (liquid formulation)
Description: Live attenuated human rotavirus vaccine containing ≥ 2x10\^6 plaque forming units (PFU) of strain G1P\[8\] per dose of 2 mL.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ROTAVIN-M1 (frozen formulation)
Description: Live attenuated human rotavirus vaccine containing ≥ 2x10\^6 PFU of strain G1P\[8\] per dose of 2 mL.
Study: NCT02132754

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166
Study: NCT01064336

Intervention type: DRUG
Intervention: Eltrombopag
Description: Eltrombopag is an orally bioavailable, small molecule thrombopoietin receptor (TPO-R) agonist for the treatment of idiopathic thrombocytopenic purpura

Intervention type: DRUG
Intervention: Eltrombopag
Description: Eltrombopag is an orally bioavailable, small molecule thrombopoietin receptor (TPO-R) agonist for the treatment of idiopathic thrombocytopenic purpura
Study: NCT02395978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-1421 Capsule
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
Study: NCT02132754

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study: NCT02431819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: contention socks
Description: Patients wear contention socks during 15 days.
Study: NCT01699763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour® NEXT LINK BGMS
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Contour® NEXT LINK BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch® UltraLink® BGMS
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® UltraLink® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nova Max Link® BGMS
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Nova Max Link® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study: NCT00390702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcatheter implantation of a VSD occluder (Nitinol coil)
Description: transcatheter implantation, by first performing a arterial-venous loop through the defect
Study: NCT03138447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Basal Insulin Titration Application
Description: Healthcare Providers (HCP) and the principal investigator (PI) will use an HCP portal to initiate a basal insulin titration algorithm. HCPs can customize the titration algorithm for every participant. Once a participant is prescribed an algorithm, they can download a mobile app on their phone with their HCPs corresponding titration plan. The app will prompt participants to enter their fasting glucose daily. Based on their fasting glucose and their HCPs titration plan, the application will display the participants daily basal insulin dose.
Study: NCT04851431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: one-to-one peer mentoring
Description: Weekly meetings with a peer family caregiver

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: one-to-one peer mentoring
Description: Weekly meetings with a peer family caregiver
Study: NCT01183325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proceed Ventral Patch placement
Description: Placement of a Proceed Ventral Patch for umbilical and small ventral hernias less than 3cm diameter with and without laparoscopic control
Study: NCT01524302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftaroline
Description: 600 mg Q12h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: 750 mg QD
Study: NCT04313049

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JACO2
Description: Performing tasks using joystick control

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JACO2
Description: Performing tasks using joystick control

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOCAL CONTROL
Description: Performing tasks using vocal control
Study: NCT00753220

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VDC2008
Description: Intratumoral injection of VDC2008 post-cryotherapy.~Dosage will depend on cohort: 2.5 x 10\^7, 7.5 x 10\^7 or 1.0 x 10\^8 cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide i.v. given at day -3 (dose: 300mg/m2); Low-dose Cyclophosphamide pill given twice daily (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles \[1 cycle = 4 weeks\] starting Week 2 after cryoablation and going to Week 26)
Study: NCT02370225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Each training session was preceded by a warm-up period, where patients were instructed to walk freely and slowly for 5 minutes, followed by 20 to 50 minutes of effective walking when they were instructed to maintain their paces to achieve the target heart rate and ending by a cold-up period for 5 minutes (similar to warm-up period).~The exercise prescription was based on the heart rate at the anaerobic threshold determined at the initial assessment. The increment of intensity exercise was based on time: 30 in the first 2 weeks, adding 5 minutes per week until eighth week, completing 60 minutes, which remains until the end.
Study: NCT02395978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-1421 Capsule
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-1421 Capsule
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-1421 Capsule
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo contained corn starch.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo contained corn starch.
Study: NCT03602963

Intervention type: DEVICE
Intervention: Dexcom G5 Mobile CGM system
Description: The accuracy and usability ot the Dexcom G5 mobile CGM system will be evaluated
Study: NCT00192270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAIV-T
Description: Each dose of the vaccine was formulated to contain approximately 1 x 10\^7 TCID50 of each of three (two subtype A and one subtype B) reassortant 6:2 influenza strains, as described above, for a total of \~3 x 10\^7 TCID50 per dose.
Study: NCT03921151

Intervention type: DRUG
Group type: OTHER
Intervention: Mirtazapine 15 MG Oral Tablet
Description: The intervention will be a 15mg of mirtazapine oral tablet given to participants prior to their treatment scan and assessments. In order to ensure that biases or social desirability do not contaminate baseline assessments, all participants will also be given a tablet consisting of dextrose in gelatin prior to their baseline scan and assessment.

Intervention type: DRUG
Group type: OTHER
Intervention: Mirtazapine 15 MG Oral Tablet
Description: The intervention will be a 15mg of mirtazapine oral tablet given to participants prior to their treatment scan and assessments. In order to ensure that biases or social desirability do not contaminate baseline assessments, all participants will also be given a tablet consisting of dextrose in gelatin prior to their baseline scan and assessment.
Study: NCT03343613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3381916
Description: IDO-1 inhibitor administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3381916
Description: IDO-1 inhibitor administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3381916
Description: IDO-1 inhibitor administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3381916
Description: IDO-1 inhibitor administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3381916
Description: IDO-1 inhibitor administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3381916
Description: IDO-1 inhibitor administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: PD-L1 inhibitor administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: PD-L1 inhibitor administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: PD-L1 inhibitor administered IV
Study: NCT01896908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium restriction
Description: Patients that are eligible and fulfill the inclusion criteria will be invited to participate while hospitalized, and then sign the informed consent form. Then, the dietitian on call will be notified in order to change the dietary map of the patients. The prescription diet for both the intervention and control group will be the same: DIET AS RESEARCH PROTOCOL. PATIENT WILL RECEIVE THE DIET UNTIL DAY __ / __ OR DISCHARGE. PLEASE DO NOT CHANGE IT. This will be combined with the medical staff and with the Nutrition and Dietetics service.~The evaluation of outcomes after hospital discharge will be held in the institution of reference when will be performed clinical evaluation and blood samples collection for neurohormonal activation analysis.
Study: NCT01615796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined
Description: Subjects receive a single dose of GSK2140944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined
Description: Subjects receive a single dose of GSK2140944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined
Description: Subjects receive a single dose of GSK2140944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined
Description: Subjects receive a single dose of GSK2140944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined
Description: Subjects receive a single dose of GSK2140944
Study: NCT05104294

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography- Angiography
Description: Peripapillary retinal nerve fiber layer thickness, ganglion cell complex, superficial and deep capillary plexus vessel density were measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography- Angiography
Description: Peripapillary retinal nerve fiber layer thickness, ganglion cell complex, superficial and deep capillary plexus vessel density were measured.